TACE Combined with Interferon-α is Safe and Effective for HCC Patiens after Curative Resection

Hepatocellular carcinoma (HCC) is one of the most common causes of cancer-related deaths worldwide. In 2008, an estimated 748, 300 new liver cancer cases and 695 900 cancer-related deaths occurred worldwide (Jemal et al., 2011). Approximately 50% of these incident cases and deaths occurred in China, among which over 90% of the incident patients were chronically infected with the hepatitis B virus (HBV) (Ferlay et al., 2010). Hepatic resection is still a major curative treatment for patients with HCC (Fan et al., 2011). However, the long-term prognosis of HCC patients following hepatic resection